- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Latham Today
By the People, for the People
AngioDynamics Beats Q3 Earnings Estimates
Medical device maker reports strong revenue growth and raises full-year guidance
Apr. 2, 2026 at 3:20pm
Got story updates? Submit your updates here. ›
AngioDynamics (NASDAQ:ANGO), a leading medical instruments supplier, announced its Q3 2026 financial results on Thursday. The company reported earnings per share of $0.02, beating analysts' consensus estimates of -$0.11 by $0.13. AngioDynamics also saw an 8.9% year-over-year increase in revenue to $78.42 million, exceeding analyst projections of $76.77 million. The strong performance led the company to raise its full-year fiscal 2026 net sales and adjusted EBITDA guidance for the third consecutive quarter.
Why it matters
AngioDynamics' better-than-expected results and raised guidance demonstrate the company's ability to navigate industry challenges like inflation and supply chain disruptions. The growth in key product lines like Auryon and the mechanical thrombectomy portfolio suggest AngioDynamics is effectively executing its strategy and gaining traction in the market. This news will be closely watched by investors as a signal of the company's overall health and competitive positioning.
The details
The Q3 revenue growth was driven by a 19% increase in the company's MedTech segment, with the Auryon product line delivering its 19th consecutive quarter of double-digit growth. The combined mechanical thrombectomy portfolio, including the AlphaVac and AngioVac products, grew approximately 18% year-over-year. Additionally, the NanoKnife revenue rose 21%, supported by the implementation of a new CPT code and expanded European indications. However, gross margin declined 110 basis points to 52.9% due to factors like tariffs, inflation, and a manufacturing transition.
- AngioDynamics reported Q3 2026 results on Thursday, April 2, 2026.
- The company raised its full-year fiscal 2026 net sales guidance to $313.5–$315.5 million and adjusted EBITDA guidance to $10–$12 million.
The players
AngioDynamics
A leading medical instruments supplier headquartered in Latham, New York, that develops, manufactures, and markets a broad range of minimally invasive medical devices.
What’s next
Investors will be closely watching AngioDynamics' continued execution and ability to maintain its growth momentum in the coming quarters.
The takeaway
AngioDynamics' strong Q3 results and raised guidance demonstrate the company's resilience in the face of industry challenges, as well as its ability to drive growth through innovative products and effective execution of its strategic priorities.
